172 related articles for article (PubMed ID: 36029331)
1. Nodal and osseous oligometastatic prostate cancer: a cohort including the introduction of PSMA-PET/CT-guided stereotactic and hypofractionated radiotherapy with elective nodal therapy.
Gawish A; Walke M; Röllich B; Ochel HJ; Brunner TB
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3937-3949. PubMed ID: 36029331
[TBL] [Abstract][Full Text] [Related]
2. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.
De Bleser E; Jereczek-Fossa BA; Pasquier D; Zilli T; Van As N; Siva S; Fodor A; Dirix P; Gomez-Iturriaga A; Trippa F; Detti B; Ingrosso G; Triggiani L; Bruni A; Alongi F; Reynders D; De Meerleer G; Surgo A; Loukili K; Miralbell R; Silva P; Chander S; Di Muzio NG; Maranzano E; Francolini G; Lancia A; Tree A; Deantoni CL; Ponti E; Marvaso G; Goetghebeur E; Ost P
Eur Urol; 2019 Dec; 76(6):732-739. PubMed ID: 31331782
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic Body Radiation Therapy Salvage for Lymph Node Recurrent Prostate Cancer in the Era of PSMA PET Imaging.
Hayek OE; Rais-Bahrami S; McDonald A; Galgano SJ
Curr Urol Rep; 2023 Oct; 24(10):471-476. PubMed ID: 37395949
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
[TBL] [Abstract][Full Text] [Related]
5. Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy.
Rogowski P; Trapp C; von Bestenbostel R; Eze C; Ganswindt U; Li M; Unterrainer M; Zacherl MJ; Ilhan H; Beyer L; Kretschmer A; Bartenstein P; Stief C; Belka C; Schmidt-Hegemann NS
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1417-1428. PubMed ID: 34628521
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
[TBL] [Abstract][Full Text] [Related]
7. 68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer.
Kalinauskaite G; Senger C; Kluge A; Furth C; Kufeld M; Tinhofer I; Budach V; Beck M; Hochreiter A; Grün A; Stromberger C
PLoS One; 2020; 15(10):e0240892. PubMed ID: 33085712
[TBL] [Abstract][Full Text] [Related]
8. Elective nodal radiotherapy with a gapless radiation field junction for oligorecurrent prostate cancer after previous radiotherapy.
Li M; Fan Y; Trapp C; Schmidt-Hegemann NS; Ma J; Buchner A; Lu S; Xu B; Stief C; Wang X; Zhou C; Belka C; Rogowski P
Clin Transl Radiat Oncol; 2023 Mar; 39():100571. PubMed ID: 36605290
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer.
Mohan R; Kneebone A; Eade T; Hsiao E; Emmett L; Brown C; Hunter J; Hruby G
Radiat Oncol; 2023 Aug; 18(1):127. PubMed ID: 37528487
[TBL] [Abstract][Full Text] [Related]
10. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
[TBL] [Abstract][Full Text] [Related]
11. Single-fraction prostate-specific membrane antigen positron emission tomography- and multiparametric magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer local recurrences.
Ehret F; Hofmann T; Fürweger C; Kufeld M; Staehler M; Muacevic A; Haidenberger A
BJU Int; 2023 Jan; 131(1):101-108. PubMed ID: 36114771
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer : An investigation of 117 pelvic lymph nodes.
Cozzi S; Botti A; Timon G; Blandino G; Najafi M; Manicone M; Bardoscia L; Ruggieri MP; Ciammella P; Iotti C
Strahlenther Onkol; 2022 Aug; 198(8):700-709. PubMed ID: 34757443
[TBL] [Abstract][Full Text] [Related]
13. Oligorecurrent Nodal Prostate Cancer: Long-term Results of an Elective Nodal Irradiation Approach.
Tran S; Jorcano S; Falco T; Lamanna G; Miralbell R; Zilli T
Am J Clin Oncol; 2018 Oct; 41(10):960-962. PubMed ID: 29315174
[TBL] [Abstract][Full Text] [Related]
14. Progression-free survival in patients with
Werensteijn-Honingh AM; Wevers AFJ; Peters M; Kroon PS; Intven M; Eppinga WSC; Jürgenliemk-Schulz IM
Acta Oncol; 2021 Oct; 60(10):1342-1351. PubMed ID: 34323648
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic Body Radiotherapy for Lymph-Nodal Oligometastatic Prostate Cancer: A Multicenter Retrospective Experience.
Cuccia F; Tamburo M; Piras A; Mortellaro G; Iudica A; Daidone A; Federico M; Zagardo V; Ferini G; Marletta F; Spatola C; Fazio I; Filosto S; Pergolizzi S; Ferrera G
Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629732
[No Abstract] [Full Text] [Related]
16. Metastasis-directed Therapy (SBRT) Guided by PET-CT
Mazzola R; Francolini G; Triggiani L; Napoli G; Cuccia F; Nicosia L; Livi L; Magrini SM; Salgarello M; Alongi F
Clin Genitourin Cancer; 2021 Jun; 19(3):230-236. PubMed ID: 32863189
[TBL] [Abstract][Full Text] [Related]
17. An Analysis of the Distribution of PSMA PET/CT-Positive Lymph Nodes and Their Coverage by Different Elective Nodal Radiation Volumes in Postoperative Prostate Cancer Patients.
Trapp C; Oliinyk D; Rogowski P; von Bestenbostel R; Ganswindt U; Li M; Eze C; Bartenstein P; Beyer L; Ilhan H; Sheikh G; Unterrainer L; Stief C; Westhofen T; Kunz WG; Unterrainer M; Belka C; Schmidt-Hegemann NS
J Nucl Med; 2023 Jun; 64(6):918-923. PubMed ID: 36732055
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy for pelvic nodal recurrences after radical prostatectomy: patient selection in clinical practice.
Panje C; Zilli T; Dal Pra A; Arnold W; Brouwer K; Garcia Schüler HI; Gomez S; Herrera F; Khanfir K; Papachristofilou A; Pesce G; Reuter C; Vees H; Zwahlen D; Putora PM
Radiat Oncol; 2019 Oct; 14(1):177. PubMed ID: 31619296
[TBL] [Abstract][Full Text] [Related]
19. Extended nodal radiotherapy for prostate cancer relapse guided with [11C]-choline PET/CT: ten-year results in patients enrolled in a prospective trial.
Fodor A; Brombin C; Deantoni CL; Giannini L; Ferrario F; Villa SL; Mangili P; Rancoita PMV; Cozzarini C; Picchio M; Del Vecchio A; Fiorino C; Di Serio MCS; Chiti A; Di Muzio NG
Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):590-603. PubMed ID: 37747578
[TBL] [Abstract][Full Text] [Related]
20.
Artigas C; Flamen P; Charlier F; Levillain H; Wimana Z; Diamand R; Albisinni S; Gil T; Velthoven RV; Peltier A; Gestel DV; Roumeguere T; Otte FX
World J Urol; 2019 Aug; 37(8):1535-1542. PubMed ID: 30824985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]